Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 14, 2013; 19(42): 7374-7388
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7374
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7374
1,3-Bis(2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of Resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells
Dipon Das, Ranjan Preet, Purusottam Mohapatra, Shakti Ranjan Satapathy, Chanakya Nath Kundu, Cancer Biology Division, KIIT School of Biotechnology, KIIT University, Bhubaneswar, Odisha 751024, India
Author contributions: Das D carried out all the experiments and wrote the first draft of the manuscript; Preet R, Mohapatra P and Satapathy SR performed the statistical analysis and were involved in editing the manuscript; Kundu CN designed the study and wrote the manuscript.
Supported by Indian Council of Medical Research and Department of Biotechnology, Government of India
Correspondence to: Chanakya Nath Kundu, Assistant professor, Cancer Biology Division, KIIT School of Biotechnology, KIIT University, Campus-11, Patia, Bhubaneswar, Odisha 751024, India. cnkundu@gmail.com
Telephone: +91-674-2725466 Fax: +91-674-2725732
Received: December 19, 2012
Revised: April 25, 2013
Accepted: June 5, 2013
Published online: November 14, 2013
Processing time: 334 Days and 13.6 Hours
Revised: April 25, 2013
Accepted: June 5, 2013
Published online: November 14, 2013
Processing time: 334 Days and 13.6 Hours
Core Tip
Core tip: 5-fluorouracil (5-FU) resistance in colon cancer patients is a common phenomenon that requires immediate resolution. In this paper, we used two commonly administered clinical drugs, 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) and Resveratrol (Res), and studied their effects on 5-FU sensitive and resistance colon cancer cells. The drug combination was more effective in 5-FU resistant cells than in 5-FU sensitive cells and was more effective than the individual treatments. The BCNU-Res combination mediated its action by compromising the base excision repair cascade. This combination might be useful for treatment of 5-FU resistant colon cancer patients.